Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

495
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
495
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.3K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.3K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.0K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Implementation of a supervised outpatient residence to support ambulatory hematopoietic stem cell transplantation: experience from Puebla, México.

Bone marrow transplantation·2026
Same author

Predicting the response to hematopoietic stem cell transplantation in persons with multiple sclerosis: the significance of an early positive response.

Bone marrow transplantation·2025
Same author

The Number of CD34 Cells Employed in Autologous Hematopoietic Stem Cell Transplantation for Persons With Multiple Sclerosis Is Not Related to the Neurological Outcome of the Procedure.

Clinical transplantation·2025
Same author

Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors.

Bone marrow transplantation·2025
Same author

Early morbimortality in autologous hematopoietic cell transplantation performed on outpatient basis in patients with autoimmune diseases: experience in 1700 patients.

Bone marrow transplantation·2025
Same author

Low iron transferrin saturation might be beneficial in the outcome of autologous transplant in multiple sclerosis.

Scandinavian journal of immunology·2025

相关实验视频

Updated: Sep 11, 2025

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

535

在多发性硬化症中的aHSCT.

Guillermo José Ruiz-Argüelles1,2

  • 1Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, Mexico.

British journal of haematology
|August 19, 2025
PubMed
概括

自主造血干细胞移植 (aHSCT) 显示出对多发性硬化症 (MS) 治疗在所有疾病形式中的承诺. 这种强大的疗法提供了一个潜在的更安全,更实惠的替代方案,新的MS药物.

科学领域:

  • 血液学 血液学 血液学
  • 神经学 神经学
  • 免疫学 免疫学 免疫学

背景情况:

  • 多发性硬化症 (MS) 是一种慢性自身免疫性疾病,影响中枢神经系统.
  • 目前用于MS的治疗方法在有效性和安全性方面存在局限性.
  • 自主造血干细胞移植 (aHSCT) 是一个新兴的治疗选择.

研究的目的:

  • 分析英国在多发性硬化症中使用HSCT的经验.
  • 评估aHSCT在不同多发性硬化症亚型中的有效性和结果.
  • 将aHSCT与MS的现有和新型治疗方法进行比较.

主要方法:

  • 对364名患有多发性硬化症 (MS) 的患者进行回顾性分析,这些患者接受了HSCT.
  • 来自英国血液和骨髓移植和细胞治疗学会 (BSBMTCT) 的数据.
  • 对复发性复发性和其他MS形式的治疗反应的评估.

主要成果:

  • 在所有类型的多发性硬化症中观察到对aHSCT的积极反应.
  • 在复发性复发性MS形式中,应答率优于复发性复发性MS.
  • aHSCT表现出令人鼓舞的结果,支持其在MS管理中的作用.
关键词:
一个HSCTCT.多发性硬化症多发性硬化症治疗治疗治疗治疗治疗治疗

更多相关视频

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.3K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.9K

相关实验视频

Last Updated: Sep 11, 2025

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

535
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.3K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.9K

结论:

  • 自主造血干细胞移植 (aHSCT) 是对多发性硬化症 (MS) 的强有力的治疗方法.
  • 与许多新型MS药物相比,aHSCT似乎更有效,更安全,更实惠.
  • 患者和家庭倡导强调HSCT作为一个重要的治疗进步.